New Dual-Targeted PET scan aims to spot cancers more clearly
NCT ID NCT07639801
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and have imaging done. The goal is to see if the dual-targeted approach improves detection accuracy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-FAPI-PSMA (a radioactive tracer for PET imaging)
- What this could lead to
- If successful, this could provide a more accurate way to detect and stage solid tumors, potentially improving treatment planning.
- What could go wrong
- This is a very early, small study with only 20 participants, so results may not apply to everyone. The new tracer may not be better than existing methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could a simple scan and blood test outsmart liver cancer?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Tumor's DNA guide better cancer care for kids?